期刊文献+

进展期非小细胞肺癌短疗程大分割姑息放疗疗效分析 被引量:9

Effect of hypofractionated palliative thoracic radiotherapy for advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:分析进展期非小细胞肺癌患者采用短疗程、大分割胸部姑息放疗(palliative thoracic radiotherapy,PTR)的疗效及其不良反应。方法:回顾性分析天津医科大学肿瘤医院2010年9月至2012年7月行PTR的ⅢB期及Ⅳ期非小细胞肺癌患者共25例,其计划靶区(PTv)剂量为45Gy/15f,单次剂量3Gv。评价PTR症状缓解情况、放疗疗效及相关不良反应。Kaplan—Meier法进行生存分析并用Log-rank进行检验。结果:除l例患者只完成36Gy/12,其余24例均完成全部放疗计划。18例患者的胸部症状得到缓解,患者咳血症状缓解率为87.5%(7/8),咳嗽为70.6%(12/17),胸痛为73.3%(11/15),呼吸困难为57.1%(8/14),声音嘶哑为50%(1/2)。PTR后胸部病灶达部分缓解(PR)+完全缓解(CR)为28%(17/25),未发现3级及以上放疗相关不良反应。患者的中位生存(overall survival,0s)为13个月(95%CI6.6~19.5个月),1年OS为51.5%(17/25)。单因素分析显示,PTR前KPS评分、PTR后化疗周期数是影响生存的重要因素。结论:对于进展期NSCLC患者,采用45Gy/15f短疗程、PTR剂量分割模式缩短了治疗时间.明显改善了患者的胸部症状,提高了OS,且近期不良反应较低,值得进一步进行大样本前瞻性随机分组研究。 Objective: To investigate the effect and toxicity of short-course and hypofractionated palliative thoracic radiotherapy (PTR) for advanced non-small cell lung cancer (NSCLC). Methods: A total of 25 patients with stage 11I B and stage 1V NSCLC, who underwent PTR from September 2010 to July 2006, were retrospectively analyzed. The PTR regime was 45 Gy in 15 fractions. Symptom relief, effect, and toxicity after completion of PTR were assessed. Survival was analyzed using the Kaplan-Meier method. Results: Except for one patient who completed only 36 Gy in 12 fractions, all other patients completed all plans. The thoracic symptoms of 18 patients were relieved. The response rates for the five main symptoms were: hemoptysis 87.5% (7/8), cough 70.6% (12/17), pain 73.3% (11/15), dyspnea 57.1% (8/14), and hoarseness 50% (1/2). The complete response and partial response after PTR was 28%, and no grade 3 or higher toxicities occurred. The median time of overall survival (OS) is 13 months (95% CI: 6.6 months to 19.5 months), and one-year OS is 51.5%. According to the univariate analysis, KPS before PTR, the number of post-PTR was significantly related to the survival. Conclusion: For advanced NSCLC patients, the PTR regime given as 45 Gy in 15 fractions evidently relieved thoracic symptoms, improved OS, and shortened treatment time. Recent relevant adverse radiotherapy reactions are low, and more prospective clinical studies must be conducted.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第20期1240-1243,共4页 Chinese Journal of Clinical Oncology
基金 天津市抗癌重大专项攻关计划项目(编号:12ZCDZSY15900)资助~~
关键词 非小细胞肺癌 放射治疗 大分割 姑息性放疗 non-small-cell lung cancer, radiotherapy, hypofractionation, palliative radiotherapy
  • 相关文献

参考文献19

  • 1Le Pechoux C.Role of postoperative radiotherapy in resectednon-small cell lung cancer:a reassessment based on new data[J].Oncologist,2011,16(5):672-681.
  • 2Fairchild A,Harris K,Barnes E,et al.Palliative thoracic radiothera-py for lung cancer:a systematic review[J].J Clin Oncol,2008,26(24):4001-4011.
  • 3Bezjak A,Dixon P,Brundage M,et al.Randomized phase IE trialof single versus fractionated thoracic radiation in the palliation ofpatients with lung cancer(NCIC CTG SC.15)[J].IntJ Radiat On-col Biol Phys,2002,54(3):719-728.
  • 4Toy E,Macbeth F,Coles B,et al.Palliative thoracic radiotherapyfor non-small-cell lung cancer:a systematic review[J].AmJ ClinOncol,2003,26(2):112-120.
  • 5Reinfuss M,Mucha-Malecka A,Walasek T,et al.Palliative thorac-ic radiotherapy in non-small cell lung cancer.An analysis of 1250patients.Palliation of symptoms,tolerance and toxicity[J].LungCancer,2011,71(3):344-349.
  • 6Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines toevaluate the response to treatment in solid tumors.European Orga-nization for Research and Treatment of Cancer,National CancerInstitute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
  • 7Trotti A,Colevas AD,Setser A,et al.GTCAE v3.0:developmentof a comprehensive grading system for the adverse effects of cancertreatment[J].Semin Radiat Oncol,2003,13(3):176-181.
  • 8Jassem J.The role of radiotherapy in lung cancer:where is the evi-dence[J].Radiother Oncol,2007,83(2):203-213.
  • 9Metcalfe SK,Milano MT,Bylund K,et al.Split-course palliativeradiotherapy for advanced non-small cell lung cancer[J].J ThoracOncol,2010,5(2):185-190.
  • 10Medical Research Council Lung Cancer Working Party.A MedicalResearch Council(MRC)randomised trial of palliative radiothera-py with two fractions or a single fraction in patients with inoperablenon-small-cell lung cancer(NSCLC)and poor performance sta-tus.Medical Research Council Lung Cancer Working Party[J].BrJCancer,1992,65(6):934-941.

二级参考文献25

  • 1Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years :analysis of the surveillance,epidemiologic,and end results database.J Clin ,2006,24:4539-4544.
  • 2Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin 0ncol,2004,31:68- 74.
  • 3Morgensztem D, Waqar S, Subramanian J, et al. Improving survival for stage 1V non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Clin Onco1,2009,4 : 1524-1529.
  • 4Kramer GW, Wanders SL, Noordijk EM, et al. Results of the Dutch national study of the palliative effect of irradiation using two different treatment schemes for non-small cell lung cancer. J Clin Onco1,2005 ,23 :2962-2970.
  • 5Fang LC, Komaki R, Allen P, et al. Comparison for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys ,2006,66 : 108-116.
  • 6Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med ,2002,346:92-98.
  • 7Kelly K, Crowley J, Bunn PA, et al. Randomized phase HI trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a southwest oncology group trial. J Clin Oncol,2001,19: 3210- 3218.
  • 8Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project : proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac 0ncol,2007,2:686-593.
  • 9Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol, 2007, 2 : 706- 714.
  • 10Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase m randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol, 2002,20: 4285-4291.

共引文献15

同被引文献67

  • 1张妮,曾维威,张献全.培美曲塞维持治疗晚期非小细胞肺癌的Meta分析[J].中国老年学杂志,2014,34(7):1774-1776. 被引量:4
  • 2赵淑红,郭建文,李超,杨克强.后程加速超分割放射治疗晚期肺鳞癌的临床研究[J].中华放射肿瘤学杂志,2004,13(2):81-83. 被引量:3
  • 3蒋华勇,吴德华,陈龙华.低分割三维适形放疗结合化疗治疗非小细胞型肺癌疗效观察[J].第一军医大学学报,2004,24(11):1297-1298. 被引量:6
  • 4Le P6choux C. Role of postoperative radiotherapy in re- sected non-small cell lung caneer:a reassessment based on new data[J]. Oncologist, 2011,16(5) :672-681.
  • 5Kang S, Koh ES, Vinod SK, et al. Cost analysis of lung cancer management in South Western Sydney[J]. J Med Imaging Radiat Oncol, 2012,56 (2) : 235-241.
  • 6Jiang J, Liang X, Zhou X, et al. Non-platinum doublets were as effective as platinum-based doublets for chemo- therapy-naive advanced non-small-ceil lung cancer in the era of third-generation agents[J]. J Cancer Res Clin On- col,2013,139(1) ..25-38.
  • 7Zukin M,Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oneology Group perform- ance status of 2 I-J3. J Clin Oncol, 2013, 31 (23) : 2849- 2853.
  • 8Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in pa- tients with non-small cell lung cancer and oligometastasis at diagnosis[J3. Int J Radiat Oncol Biol Phys, 2012,84 (I) .. e61-67.
  • 9Iwhild A, Hams K,Barnes E, et al. Palliative thoracic Ra- diotherapy for lung cancer: a systematic review[J]. J Clin0nc01,2008,26:4001-4011.
  • 10Mfiry B, Guy JB, Swalduz A, et al. The evolving locally-ad- vanced non-small cell lung cancer landscape: Building on past evidence and experience[J]. Crit Rev Oncol Hematol, 2015, 96(2) .-319-327.

引证文献9

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部